Brief: Epirus Biopharmaceuticals entered settlement satisfaction amendment with Livzon Mabpharm

Epirus Biopharmaceuticals

25/07/2016 16:33

July 25 (Reuters) - Epirus Biopharmaceuticals Inc  EPRS.O : 
    * On July 15, co entered into a settlement satisfaction 
amendment with Livzon Mabpharm Inc - SEC filing 
    * On July 25, co filed a voluntary petition for relief under 
provisions of Chapter 7 of title 11 of United States code 
    * Assets of company will be liquidated and claims paid in 
accordance with code 
    * Also assigned to Livzon its rights, title and interest to 
all BOW070 cell-line clones and development reports, related 
materials 
    * Company's board of directors terminated employment of 
company's remaining employees 
    * All of company's directors have resigned from their 
positions as directors of company 
    * Co sublicensed to livzon exclusive rights in certain 
territories with respect to company's bow070 technology 
    * Settlement satisfaction amendment relating to conveyance 
of certain of co's rights related to its BOW070 biosimilar 
product 
    * Says on July 18, entered into a settlement satisfaction 
agreement with Reliance Life Sciences Pvt. Ltd 
    * Scott Rocklage resigned from his position as the company's 
chief executive officer 
 
Source text (http://bit.ly/2a90JLF) 
Further company coverage:  EPRS.O  
 
 ((Bengaluru Newsroom +1 646 223 8780;))